Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer Healthcare professionals are concerned that hormone insulin meds, often the key diabetes treatment, are getting too costly for many patients, even in the U.S. In developing ...

Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand Plenty of Bayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, ...

Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

Emily Wasserman U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling. FiercePharma ...

Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Tracy Staton Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times ...

GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

Intas CEO expects to break into U.S. biosimilar market yet this year

Eric Palmer The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex. FiercePharma ...

India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

Eric Palmer India's Cipla has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative ...

More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Tracy Staton Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $ 14,100 per year. But even after pharmacy ...

UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.

Eric Palmer With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $ 2 billion on its first API plant in the U.S., ...

Novo says new U.S. plant may be best bet to offset the FX bite

Eric Palmer Novo Nordisk has forecast that currency hedging losses will leave it with an $ 850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have ...

Takeda taps Lilly exec to run U.S. unit, adding a woman to its all-male exec team

Tracy Staton Takeda has chosen a woman to run its U.S. pharma business, just weeks after new CEO Christophe Weber said he was unhappy with the gender balance in the Japanese drugmaker's ...
Page 1 of 912345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS